Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates
- 31 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 31 (5), 695-701
- https://doi.org/10.1007/s10096-011-1360-5
Abstract
Fosfomycin represents a potential last-resort treatment option for infections with certain multidrug-resistant (MDR) Gram-negative pathogens. We evaluated double-drug combinations of fosfomycin with imipenem, meropenem, doripenem, colistin, netilmicin, and tigecycline for in vitro synergy against 100 MDR Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates, using the Etest method. Synergy was defined as a fractional inhibitory concentration index ≤0.5. The isolates were consecutively collected at a university hospital in Greece from various clinical specimens. Against 50 serine carbapenemase-producing K. pneumoniae isolates, synergy of fosfomycin with imipenem, meropenem, doripenem, colistin, netilmicin, and tigecycline was observed for 74.0%, 70.0%, 74.0%, 36.0%, 42.0%, and 30.0% of the isolates, respectively. Against 14 extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae isolates, synergy of fosfomycin with imipenem, meropenem, doripenem, colistin, netilmicin, and tigecycline was observed for 78.6%, 42.9%, 42.9%, 7.1%, 42.9%, and 21.4%, respectively; for 20 ESBL-producing E. coli isolates, the corresponding values were 55.0%, 25.0%, 30.0%, 15.0%, 25.0%, and 25.0%; and for 15 MDR P. aeruginosa isolates, the corresponding values were 46.7%, 53.3%, 73.3%, 13.3% , 13.3%, and 13.3%. Antagonism was not observed for any of the combinations tested. Further studies are needed in order to confirm the clinical relevance of the above findings.Keywords
This publication has 33 references indexed in Scilit:
- Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa InfectionsPLOS ONE, 2010
- Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infectionsInternational Journal of Antimicrobial Agents, 2009
- Fosfomycin: an old, new friend?European Journal of Clinical Microbiology & Infectious Diseases, 2009
- Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasisJournal of Antimicrobial Chemotherapy, 2009
- Prospective Observational Study of the Impact of VIM-1 Metallo-β-Lactamase on the Outcome of Patients with Klebsiella pneumoniae Bloodstream InfectionsAntimicrobial Agents and Chemotherapy, 2009
- Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal InfectionsClinical Infectious Diseases, 2008
- Evaluation of Methods To Identify the Klebsiella pneumoniae Carbapenemase in EnterobacteriaceaeJournal of Clinical Microbiology, 2007
- Carbapenemases: the Versatile β-LactamasesClinical Microbiology Reviews, 2007
- Extended-Spectrum β-Lactamases: a Clinical UpdateClinical Microbiology Reviews, 2005
- In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin againstPseudomonas aeruginosaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997